INVO Fertility Reports Going Concern, Restates Financials, Discloses Material Weaknesses, and Faces Nasdaq Delisting Risk
IVF is trading near its 52-week low of $1.38 (8.3% above the low) on elevated volume (3.0× avg).
Summary
INVO Fertility's annual report reveals substantial doubt about its ability to continue as a going concern, restates prior interim financials due to errors, and identifies material weaknesses in internal controls, all while facing Nasdaq delisting for late filings.
Key Events · Corporate Governance and Compliance · IVF
-
Going Concern Warning
The company reported an accumulated net loss of $91.4 million since inception and explicitly stated "substantial doubt about our ability to continue as a going concern" for at least the next year.
-
Financial Restatement
Interim financial statements for Q1-Q3 2025 were restated to correct material errors related to preferred stock and warrant classifications, derivative liabilities, gain on settlement, and debt extinguishment accounting.
-
Material Weaknesses in Internal Controls
Management concluded that internal control over financial reporting was not effective as of December 31, 2025, citing limited segregation of duties and inadequate accounting resources for complex transactions.
-
Nasdaq Delisting Threat
The company received Nasdaq notices on April 23, 2026, and May 27, 2026, for failing to timely file its 10-K and 10-Q reports, requiring a compliance plan to avoid delisting.
Analysis · IVF · Industrial Applications And Services
INVO Fertility's annual report reveals a dire financial situation with a going concern warning, significant accounting errors requiring restatement of prior interim financials, and critical weaknesses in internal controls. These issues, coupled with multiple reverse stock splits and ongoing Nasdaq non-compliance, indicate severe operational and financial instability. The company's repeated reliance on dilutive financings with unfavorable terms highlights its desperate need for capital. Investors face substantial risk, including potential delisting and further dilution.
At the time of this filing, IVF was trading at $1.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $1.38 to $209.54. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.